Get the Stockscreener App
3.86
5.18%
0.19
After Hours:
4.03
0.17
+4.40%
Nucana Plc Adr stock is traded at $3.86, with a volume of 529.24K.
It is up +5.18% in the last 24 hours and down -18.05% over the past month.
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
See More
Previous Close:
$3.67
Open:
$3.85
24h Volume:
529.24K
Relative Volume:
0.55
Market Cap:
$6.22M
Revenue:
-
Net Income/Loss:
$-33.44M
P/E Ratio:
-0.2409
EPS:
-16.0242
Net Cash Flow:
$-28.30M
1W Performance:
+34.49%
1M Performance:
-18.05%
6M Performance:
-97.62%
1Y Performance:
-99.24%
1-Day Range:
$3.85
$4.23
1-Week Range:
$2.82
$4.23
52-Week Range:
$2.78
$1,650.00
Nucana Plc Adr Stock (NCNA) Company Profile
Compare NCNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NCNA
Nucana Plc Adr
|
3.86 | 6.22M | 0 | -33.44M | -28.30M | -16.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Nucana Plc Adr Stock (NCNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-30-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-03-22 | Downgrade | Cowen | Outperform → Market Perform |
| Oct-22-20 | Initiated | Truist | Buy |
| Jul-24-20 | Initiated | Oppenheimer | Outperform |
| Aug-19-19 | Initiated | H.C. Wainwright | Buy |
| Oct-19-18 | Initiated | Piper Jaffray | Overweight |
| Oct-23-17 | Initiated | Citigroup | Buy |
| Oct-23-17 | Initiated | Jefferies | Buy |
| Oct-23-17 | Initiated | William Blair | Outperform |
View All
Nucana Plc Adr Stock (NCNA) Latest News
NuCana compliant with all Nasdaq continued listing criteria - MSN
Rising Momentum in European ADRs: A Strategic Entry Point for US Investors - AInvest
NuCana to Present Data on NUC-7738’s Synergy with PD-1 Inhibitors at the ESMO Congress 2025 - GlobeNewswire Inc.
What recovery options are there for NuCana plc Depositary ReceiptJuly 2025 Update & Expert Curated Trade Ideas - Newser
How institutional ownership impacts NuCana plc Depositary Receipt stockWeekly Trade Recap & Accurate Trade Setup Notifications - Newser
Wall Street Today: Dow, Nasdaq, S&P 500 open flat as investors focus on China tariff deadline; Nvidia down 1.3% - Mint
NuCana plc ADR’s Shares Reel: -92.65% Quarterly Revenue Decline Amid 14.58M Market Cap - investchronicle.com
HEPS’s Stock Dilemma: D-MARKET Electronic Services & Trading ADR’s Market Performance and Outlook - investchronicle.com
NuCana plc Announces Change in American Depository Shares Ratio to Enhance Liquidity and Nasdaq Compliance - Quiver Quantitative
GIBO Holdings Ltd (NASDAQ: GIBO): Down -99.40% In 2025, Outlook Remains Negative - stocksregister.com
What is the dividend policy of NuCana plc Depositary Receipt stockTremendous gains - jammulinksnews.com
NuCana Stock Set to Reverse Split on Friday, August 8th (NASDAQ:NCNA) - Defense World
NuCana completes cancellation of all remaining Series A Warrants - Investing.com
NCNA’s Market Whiplash: -98.30% YTD Decline, -65.02% Plunge in 30 Days - investchronicle.com
NuCana Announces ADS Ratio Change to Enhance Liquidity - The Globe and Mail
NuCana (NCNA) Announces 1-for-200 Reverse ADS Split Effective Aug 8 2025 - Stock Titan
NuCana to implement 1:200 reverse ADS split to boost share price - Investing.com
Nucana Plc shares surge 45% in premarket after receiving Nasdaq delisting notice and strong industry performance. - AInvest
NuCana enters $100 million at-the-market sales agreement for ADS offering - Investing.com
NuCana CEO takes leave of absence due to health reasons - Investing.com
Market Insight: RxSight Inc (RXST)’s Notable Drop, Closing at 13.50 - DWinneX
The Future of NuCana plc ADR: Analyzing NCNA - investchronicle.com
nucana plc announces annual report release and upcoming agm - Investing.com India
NuCana's Melanoma Breakthrough: Key Drug Advances to Expansion Trial, Q1 Losses Drop 63% Year-over-Year - Stock Titan
Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket - Benzinga
NuCana prices $7 million direct offering of ADSs and warrants - Investing.com
NuCana prices $7 million direct offering of ADSs and warrants By Investing.com - Investing.com India
New Outlook On NuCana plc ADR - Stocksregister
NCNA’s Stock Journey: What Investors Need to Know About NuCana plc ADR’s Performance - investchronicle.com
Do investors need to be concerned about Cadiz Inc (CDZI)? - uspostnews.com
Natera Inc (NTRA) deserves closer scrutiny - uspostnews.com
Weave Communications Inc (WEAV) produces promising results - uspostnews.com
Investing in NuCana plc ADR (NCNA) might be an excellent idea, but the stock is currently overvalued/undervalued - uspostnews.com
Will Pfizer's Non-COVID Drugs Drive Sales Again This Earnings Season? - Nasdaq
Post-Trade Analysis: NuCana plc ADR (NCNA) Slides -26.97, Closing at 0.65 - DWinneX
Closing Bell Recap: Yxt.Com Group Holding Ltd. ADR (YXT) Ends at 0.56, Reflecting a -14.42 Downturn - DWinneX
In the Green: Gogoro Inc (GGR) Closes at 0.26, Up/Down 0.08 from Previous Day - DWinneX
Daily Market Movement: Tivic Health Systems Inc (TIVC) Sees a 1.88 Increase, Closing at 7.04 - DWinneX
RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks - Barchart.com
Stock Update - Investorsobserver
NuCana secures new US patent for cancer treatment NUC-7738 - Investing.com
NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study - Yahoo Finance
NuCana stock downgraded by William Blair after halted cancer study - Investing.com
NuCana shares receive $150 stock PT at Oppenheimer on upbeat trial prospects - Investing.com
NuCana regains Nasdaq compliance with bid price rule - Investing.com
NuCana: Potential Turnaround In 2024 But Risky - Seeking Alpha
NuCana plcADR (NCNA) Price Target Increased by 15.39% to 5.10 - Nasdaq
Here's Why NuCana PLC Sponsored ADR (NCNA) is Poised for a Turnaround After Losing 26.5% in 4 Weeks - Yahoo Finance
Down 34.6% in 4 Weeks, Here's Why You Should You Buy the Dip in NuCana PLC Sponsored ADR (NCNA) - Yahoo Finance
Down 57.3% in 4 Weeks, Here's Why You Should You Buy the Dip in NuCana PLC Sponsored ADR (NCNA) - Nasdaq
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - Business Wire
Nucana Plc Adr Stock (NCNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):